Among the many latest approvals, the US Food and Drug Administration (FDA) has approved Blujepa (gepotidacin) for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women who weigh 40 kg or more and for children who are 12 years and older and weigh 40 kg or more.What Is Blujepa?It is a first-in-class oral antibiotic which is approved for the treatment of uUTIs which are caused by Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus, and Enterococcus faecalis.How Was It Approved?The approval followed the results form the Phase 3 EAGLE-2 and EAGLE-3 trials. These trials were useful to demonstrate the medication's noninferiority and superiority, respectively, to nitrofurantoin, which is one of the leading current standard-of-care options available for uUTIs in women and pediatric patients. This is for patients with confirmed uUTI.What were the results of these trials?In EAGLE-2, the therapeutic success occurred in 50.6 percent of patients taking Blujepa compared with 47.0 percent of those taking nitrofurantoin. In EAGLE-3, the superiority was demonstrated for Blujepa versus nitrofurantoin, with therapeutic success occurring in 58.5 versus 43.6%.Are there any side effects of Blujepa?One of the most common adverse events that patients who have consumed Blujepa reported was gastrointestinal, including diarrhea, which was reported in 16% of the patients. Then came nausea at 9%.The maximum severity of these side effects or adverse events were mostly mild up to 69% to moderate at 28%. Severe gastrointestinal events occurred only in less than 1% of all the participants."The approval of Blujepa is a crucial milestone, with uUTIs among the most common infections in women," Tony Wood, chief scientific officer of GSK, said in a statement. "We are proud to have developed Blujepa, the first in a new class of oral antibiotics for uUTIs in nearly three decades, and to bring another option to patients given recurrent infections and rising rates of resistance to existing treatments."What Is Uncomplicated UTI?As per the National Library of Medicine's National Center for Biotechnology Information, an uncomplicated UTI is a bacterial infection of the bladder and associated structures. Patients with uUTI have no structural abnormality of the urinary tract and no comorbidities such as diabetes, an immunocompromised state, recent urologic surgery, or pregnancy. A uUTI is also known as cystitis or lower tract UTI.The presence of bacteria (bacteriuria) or white blood cells (pyuria) in the urine without symptoms does not indicate a urinary tract infection (UTI). Common UTI symptoms include frequent urination, urgency, suprapubic discomfort, and pain during urination (dysuria). While UTIs are common in women, they are rare in circumcised males. When they do occur in circumcised males, they are typically classified as complicated UTIs.Many uncomplicated UTIs can resolve on their own, but treatment is often sought to relieve symptoms and prevent the infection from spreading to the kidneys. If left untreated, a UTI can develop into an upper tract infection like pyelonephritis, which can damage kidney structures and potentially lead to high blood pressure.A UTI diagnosis is based on clinical history and urinalysis, with confirmation through a urine culture. Proper urine sample collection is crucial for accurate evaluation and diagnosis.